Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 20,000
- Avg volume
- 51,470
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 4%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for vi...
Show more
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. The company was incorporated in 1999 and is based in Sydney, Australia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 61 2 9300 3344
- Website
- https://www.biotron.com.au
- Address
- 66 Hunter Street, Level 2, Sydney, Australia
Latest news
No headlines yet.
